Omnicell (STU:OC9) Change In Receivables : €69 Mil (TTM As of Mar. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Omnicell Change In Receivables?

Omnicell's change in receivables for the quarter that ended in Mar. 2024 was €3 Mil. It means Omnicell's Accounts Receivable declined by €3 Mil from Dec. 2023 to Mar. 2024 .

Omnicell's change in receivables for the fiscal year that ended in Dec. 2023 was €45 Mil. It means Omnicell's Accounts Receivable declined by €45 Mil from Dec. 2022 to Dec. 2023 .

Omnicell's Accounts Receivable for the quarter that ended in Mar. 2024 was €229 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Omnicell's Days Sales Outstanding for the three months ended in Mar. 2024 was 92.13.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Omnicell's liquidation value for the three months ended in Mar. 2024 was €-306 Mil.

Omnicell Change In Receivables Historical Data

The historical data trend for Omnicell's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Omnicell Change In Receivables Chart

Omnicell Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-19.39

30.28

-36.26

-56.98

45.07

Omnicell Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															-20.69	44.88	0.55	20.27	3.12

Omnicell Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €69 Mil.

Omnicell (STU:OC9) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Omnicell's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	228.631	/	226.459	*	91
=	92.13

2. In Ben Graham's calculation of liquidation value, Omnicell's accounts receivable are only considered to be worth 75% of book value:

Omnicell's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	482.449	-	1007.545	+	0.75 * 228.631	+	0.5 * 95.189
=	-306

Omnicell Change In Receivables Related Terms

Thank you for viewing the detailed overview of Omnicell's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Omnicell (STU:OC9) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Omnicell Inc (STU:OC9) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

OMCL:USA

Address

2625 Augustine Drive, Suite 301, Santa Clara, CA, USA, 95054

Website

https://www.omnicell.com

Omnicell Inc provides automation and business analytics software for healthcare providers. The automation and analytics segment manufactures medication dispensing systems, pharmacy inventory management systems, and related software. The medication adherence segment sells products like consumable medication blister cards and packaging equipment to help administer medication outside of a hospital setting. Omnicell generates the vast majority of its revenue in the United States.

Omnicell (STU:OC9) Headlines

No Headlines